Cancer-associated fibroblasts (CAF) are key contributors to malignant progression, but their critical regulators remain largely unknown. In this study, we examined the role of Twist1, a central regulator of epithelial-mesenchyme transition in carcinoma cells, in the transdifferentiation of normal quiescent fibroblasts to CAF and we 
Introduction
Tumor growth and progression are markedly influenced by the tumor microenvironment (TME), which comprises the extracellular matrix (ECM) and a variety of stromal cells, such as fibroblast, monocytes, and endothelial cells (1, 2) .
Fibroblasts are the most common cells in connective tissue, and their main function is to maintain the ECM and regulate epithelial differentiation by stromal-epithelial crosstalk (3, 4) . Fibroblasts display a wide spectrum of activation states: normal fibroblasts show thin, wavy, small spindle cell morphology, whereas activated fibroblasts are large, plump, spindle-shaped mesenchymal cells with stress fibers (1, 3) . Among activated fibroblasts, those found in association with cancer cells are known as cancer-associated fibroblasts (CAFs) (3).
CAFs promote cancer progression through remodeling of the ECM, induction of angiogenesis, and recruitment of inflammatory cells and directly stimulate cancer cell proliferation via the secretion of growth factors and mesenchymal-epithelial cell interactions (5) . Although CAF's biological and clinical significance in tumor microenvironment has been widely recognized, the mechanism by which normal fibroblasts are transformed into CAFs remain vastly unknown.
In our previous study, we showed that Twist1 is expressed in stromal fibroblasts in gastric cancer tissues and that Twist1 expressing fibroblasts possess CAF-like properties (6) . Twist1 is a basic Helix-Loop-Helix transcription factor that is essential for the development of mesodermally-derived tissues (7, 8) . During mouse embryogenesis, Twist1 is expressed in various mesodermal tissues including neural crest-derived mesenchyme, branchial arch, muscle, bone, and fibroblasts (9, 10). Author Manuscript Published OnlineFirst on November 3, 2014; DOI: 10.1158/0008-5472.CAN- adult tissues and limited to mesenchymal stem cell (11, 12) and human white adipocyte (13) . On the other hand, Twist1 is known to be an important inducer of epithelial-mesenchymal transition (EMT) and Twist1 overexpression has been reported in a variety of epithelial cancer cells with clinical correlation with poor prognosis (14) (15) (16) . However, despite the abundance of Twist 1 expressing stromal fibroblasts within cancer tissue, its clinical significance and regulating mechanism remain almost completely unknown.
In the present study, we investigated molecular mechanism by which Twist1 is induced in cancer associated fibroblasts and the role of Twist1 in driving the transdifferentiation of quiescent fibroblasts into CAFs. In addition, we showed that Twist1 expression is necessary and sufficient for CAF transdifferentiation.
Materials and Methods

Cell lines
The gastric normal fibroblast cell line Hs738 was obtained from the American Type Culture Collection (ATCC). Hs738 and the stomach cancer cell lines MKN1, MKN28, MKN74, NCI-N87, SNU638, and SNU668, and the breast cancer cell line MCF-7 were used. Cell lines were purchased from the Korean Cell Line Bank (Seoul, Korea) that performs cell line characterizations using DNA fingerprinting analysis and passaged in our laboratory for fewer than 6 months. Maintenance procedures are described in Supplementary Methods.
Isolation and culture of fibroblasts
Human stomach tumor specimens were obtained from patients undergoing 
Incubation of fibroblast with conditioned Media from gastric cancer cells
Detailed procedures are described in Supplementary Methods.
Tissue specimens and construction of tissue microarrays (TMA)
A total of 332 FFPE gastric tissue samples were included in this study. All patients provided written informed consent according to institutional guidelines. Detailed procedures are described in Supplementary Methods.
Immunohistochemical analysis
Detailed methods and list of antibodies used were described in Supplementary Methods.
Senescence-associated ȕ-galactosidase (SA-ȕ-gal) activity assay
ELISA for CXCL12/SDF1a
The concentration of CXCL12/SDF1a was estimated in CM (conditioned media) from NF#14 (GFP/Twist1), NF#32 (GFP/Twist1), CaF#14 (ShNS/Shtwist1), and CaF#32 (ShNS/Shtwist1). Detailed procedures are described in Supplementary Methods.
Cell viability/proliferation assay
Stomach cancer cells were cultured with CM from normal and CAFs for 2 days.
Cells were detached, seeded in 96 well plates, and cultured for 24 hrs. Detailed procedures are described in Supplementary Methods. and MCF-7+GFP cells were infected with IL-6 expressing lentivirus. Tumor cells (3×10 6 ; SNU638 and 2×10 6 ; MCF7) were implanted subcutaneously in the right flank in 0.1 ml of serum-free medium and growth factor reduced matrigel (1:1). Tumor volume was determined every 2 weeks.
Xenograft model
Lentivirus transduction.
Detailed procedures are described in Supplementary Methods. Detailed procedures and primer sequences are described in Supplementary Methods.
RNA extraction and quantitative real-time RT-PCR
SDS-PAGE
Invasion/Migration assay
ChIP assay
CAF#14 cells were grown to 70í80% confluency and fixed with 1% formaldehyde.
Nuclear extracts were sonicated to shear the DNA into fragments smaller than 500 bp. Twist1-DNA complexes were immunoprecipitated using Protein G Dynabeads (Cat. 10003D, Invitrogen, USA) conjugated with anti-Tiwst1 IgG or control mouse IgG.
After the precipitated DNA was eluted, crosslinks were reversed by 0.3 M NaCl and purified with the QIAquick PCR Purification Kit (28104, Qiagen, CA). PCR was performed on the purified DNA using primer sets as described in Supplementary Methods.
Luciferase assay
The pGL3.CXCL12 promoter (í1442 to +28) luciferase vector was generated by inserting cxcl12 promoter sequence. The 293T cells (5×10 4 Lipofectamine 2000 (Invitrogen). Luciferase reporter gene assays were performed using the Luciferase assay system (Promega). Sequences were available in Supplementary Methods.
Site-directed mutagenesis
The Twist1 binding E-BOX-1 region (CAGGTG) and non-binding E-BOX-2 region (CATCTG) on the CXCL12 promoter were mutated using the pGL3.CXCL12 (í1442 to +28) luciferase vector as the template DNA. The PCR amplification for sitedirected mutagenesis was performed using the corresponding mutant primers. The sequence changes for the E-BOX-1(í514 bp to í509 bp) htwist1 binding site were as follows: WT, GAGGTG and mutant E-BOX-1, TTGGTG. The sequence changes for the E-BOX-2(í1042 to í1037) were as follows: WT, CATCTG; and mutant E-BOX-2, TTTCTG. Sequences were available in Supplementary Methods.
Immunofluorescence assay
Paraffin sections from MKN74, SNU638 and MCF7 xenograft models were used and detailed procedures are described in Supplementary Methods.
TCGA Data
mRNA expression data were obtained for 9 tumors of TCGA carcinoma project through the cBio cancer genomics portal (http://www.cbioportal.org/public-portal).
Gene expression microarray
Data have been deposited in Gene Expression Omnibus (accession number GSE62740). Expression profiling analysis was performed using the Agilent Oligo 
High throughput sequencing
Genomic DNA was isolated from two patients for each cancer cell, matched CAFs, and matched normal fibroblasts. Library construction and targeted exome capture (505 genes) using the Agilent SureSelect Target Enrichment System were performed.
Sequencing of exome-enriched libraries was performed using Illumina's MiSeq System. Average target coverage was 138.3 for the six tested samples and more than 90% of target bases achieving 30X coverage were obtained in all six samples.
Detail methods and sequencing metrics are available in Supplementary Methods.
Statistical Analysis
Detailed methods are described in Supplementary Methods.
Results
Twist1 upregulation by the IL-6/STAT3 axis in quiescent fibroblasts with the expression of CAF markers
In a previous study, we showed that Twist1 is expressed in CAFs derived from gastric cancer tissues with significant associations with CAF markers expression and poor clinical outcome (6) . Despite these results suggesting the importance of Twist1 in CAFs, the mechanism by which Twist1 is activated in fibroblasts remains unknown. were established from gastric non-tumor tissues. When we cultured these normal fibroblasts with conditioned medium (CM) from four gastric cancer cell lines (MKN28, 74, NCI-N87, and SNU668), only CM from SNU668 significantly up-regulated mRNA levels of CAF markers, including FAPĮ, FSP1, PDGFRĮ, and Twist1 ( Figure 1A , B).
Next, we searched for cytokines selectively secreted by SNU668 because cytokines are important soluble factors in CM for CAF activation (17) . The mRNA levels of cytokine genes obtained from the BioCarta data set for gastric cancer cell lines were validated using gene expression data from TCGA project. The results showed that IL-6 mRNA levels were distinctly high in SNU668 cells compared to those of other cell lines ( Figure 1C ). IL-6 protein levels were also markedly increased in the CM of SNU668 ( Figure 1D ), suggesting that IL-6 is a major inducer of CAF transdifferentiation. To test this hypothesis, the effect of IL-6 blocking on CAF transdifferentiation was evaluated by adding IL6-blocking antibody to CM from SNU668 cells, which abolished the enhanced expression of Twist1 and CAF markers induced by CM of SNU668 ( Figure 1E ). Furthermore, acquired CAF phenotype in fibroblast by IL6 was maintained even after removal of IL6 (Supplementary Figure 1) .
Next, gastric normal fibroblasts were treated with IL-6 at 50ng/ml for 2 days and its impact on the expression of CAF markers was assessed by western blot analyses. indicating that these cells were CAFs not originated from cancer cells ( Figure 2D ).
This experiment was repeated using another gastric cancer cell, MKN74 and identical result was obtained (Supplementary Figure 3) .
The expressions of IL-6, pSTAT3, and Twist1 in gastric cancer tissues were studied using immunohistochemistry and IL-6 expression was prevalent in the cancer stroma in all cases (n=46). pSTAT3 expression was detected in both cancer cells and stromal fibroblasts, whereas Twist1 expression was mainly limited to CAFs.
There was a significant correlation between pSTAT3 and Twist1 expression in CAFs (P<0.001) ( Figure 2F ). 
Twist1 expression is sufficient for transdifferentiation of quiescent fibroblasts to CAFs
To determine whether Twist1 alone confers normal fibroblast with CAF like properties, gastric normal fibroblasts (Hs738, NF#19, and NF#32) were induced to express Twist1 using lentivirus, and we found that the protein levels of CAF markers, such as FAPĮ, PDGFRĮ, PDGFRȕ, Į-SMA, and FSP1, were enhanced by Twist1 in these normal fibroblasts ( Figure 3A and Supplementary Figure 2D 
and invasion of gastric cancer cells was also remarkably reduced by knock-down of Twist1 in gastric CAFs ( Figure 4D ). These results indicate that Twist1 is necessary for CAF transdifferentiation and essential for the maintenance of the CAF phenotype. 
Genome
CXCL12, a potent regulator of the CAF phenotype, is directly upregulated by
Twist1 in fibroblasts with clinical relevance
Based on the results of our gene-chip study and functional significance of CXCL12 as a strong tumor-promoting chemokine, we suspect that CXCL12 is a key target of Twist1 in CAFs (19, 20) . First, we validated our mRNA microarray results in both mRNA and protein levels. We confirmed that the secretion of CXCL12 was markedly enhanced by Twist1 alone in normal fibroblast (NF#32) and Twist1 is also essential for CXCL12 secretion in CAF (CaF#32) using ELISA assay ( Figure 5A ). Besides, Twist1 overexpression increased the mRNA level of CXCL12 in normal fibroblasts (NF#14 and NF#32), whereas knock-down of Twist1 decreased the mRNA level of CXCL12 in CAFs (CAF#14 and CAF#32) ( Figure 5B ). The association between Twist1 and CXCL12 was analyzed in other types of cancer using public mRNA expression data from TCGA, which showed a significant correlation between Twist1 and CXCL12 expression in various cancers, such as breast, colorectal, ovarian, endometrial, lung, thyroid, and renal cancers, and glioblastoma (Supplementary Figure 5) . These results suggest that Twist1 regulates CXCL12 expression at the transcriptional level.
To further examine the regulation of CXCL12 by Twist1, we performed luciferase reporter assays using the pGL3.CXCL12 vector carrying the CXCL12 promoter region ( Figure 5C ). The pGL3.CXCL12 and pSG5.hTwist1.HA vectors were transiently co-transfected into NIH3T3 cells. As shown in Figure 5D , the CXCL12 promoter-reporter activity was significantly affected when Twist1 was introduced into on CXCL12 promoter activity, whereas mutation of the distal E-box (í1037) made no difference, indicating that the proximal E-box is crucial for Twist1 function. Next, we performed chromatin immunoprecipitation (ChIP) assays in endogenous Twist1-expressing CAFs (CaF#14). Specific primer sets for the known Twist1-binding E-box CACATG (PDGFRĮ; í1839 to í1834 bp) in the PDGFRĮ promoter were used as a positive control (17) . Twist1 bound specifically to the positive control (PDGFRĮ; í1839 to í1834 bp) and the proximal E-box CAGGTG ( Figure 5E ), whereas no amplification was detected in the distal E-box (E-box2) or in the NC site containing no E-box sequence ( Figure 5E ). These results indicate that Twist1 binds directly to the endogenous CXCL12 promoter.
In gastric cancer tissues, CXCL12 is expressed in both cancer cells and stromal cells and there is a significant correlation in stromal expressions between CXCL12 and Twist1 (P<0.001) ( Figure 5F ). In addition, stromal expression of CXCL12 was associated with an unfavorable clinical outcome (P=0.0232) ( Figure 5G ). Patients' group with both Twist1 and CXCL12 expressing CAFs had the worst prognosis, whereas the other group in which CAFs were negative for both Twist1 and CXCL12 had the best prognosis, and the difference was statistically significant (P<0.001) 
Twist1 contributes to perpetual CAF activation by repressing the senescence of fibroblasts and CAFs
One of the CAF-specific properties that distinguishes them from normal activated fibroblasts such as myofibroblast is their constitutive activation (3). In contrast to CAFs, myofibroblasts activated during conventional inflammation regress to a normal state through senescence or apoptosis after the source of inflammation is removed 
Discussion
In our previous study, we showed that Twist1 is frequently overexpressed in stromal fibroblasts surrounding gastric cancer cells (6) . And these Twist1-expressing stromal fibroblasts also expressed CAF markers such as FSP1 and PDGFRĮ with association with poor prognosis (6) . Despite these results, there was no direct evidence for functional role of Twist1 as a key regulator of CAFs. Therefore, in the present study, we established fibroblasts and CAFs models from gastrectomy specimens and confirmed that Twist1 expression is necessary and sufficient for CAF transdifferentiation. In addition, IL6/STAT3 axis was discovered to be a key upstream control of Twist1. Microarray analysis of Twist1's effect on mRNA expression in fibroblasts identified CXCL12 as a key Twist1's target in CAFs. Moreover, Twist1 was revealed to suppress cellular senescence of normal fibroblasts and CAFs.
Since Yang et al. first reported that Twist1 is a critical player in cancer metastasis (16) , most studies focused on Twist1's role in cancer cells (22) (23) (24) , with little attention paid to its possible role in the tumor microenvironment, including CAFs. In contrast to rare expression of Twist1 in adult normal fibroblast, Twist1 is frequently and strongly expressed in embryonic fibroblast (9, 11, 25) and pathologic fibroblasts in idiopathic pulmonary fibrosis (26, 27) in mesenchymal stem cell is mediated by Twist activation. This result is highly consistent with our result and also highlights the importance of Twist1 in CAF (29) .
The role of Twist1 as a major EMT inducer implicates that certain Twist1-expressing CAFs may be derived from malignant epithelial cells. However, EMT of cancer cells probably accounts for only a fraction of CAFs (3, 30) . In this present study, CAFs isolated from tumors showed no mutation in contrast to their matched cancer cells displaying more than 9 mutations ( Figure 4A ). Despite a few previous studies claiming that CAFs are genetically abnormal, recent evidences showed CAFs to be genetically normal (31, 32) . No somatic mutations were detected in CAF cultures generated from primary pancreatic adenocarcinomas (32, 33) . In addition, we also found that Twist1-expressing stromal cells in xenograft formed by ectopic GFP/IL6 expressing cancer cells were negative for GFP (Figure 2 
fibroblasts and CAFs. Indeed, Twist1 was revealed to be induced by the IL6/STAT3 axis in gastric normal fibroblasts and was indispensable for IL-6 induced CAF transdifferentiation (Figure 1) . Furthermore, IL-6 was abundant in the cancer stroma and a significant positive correlation between pSTAT3 and Twist1 was observed in cancer tissues ( Figure 2F ).
In the present study, we searched for Twist1 target genes in CAFs using mRNA microarray and most of identified candidate genes, such as CXCL12 and Tn-C were previously reported to be CAF phenotype-related (19, 20, 40) . Orimo et al. reported that CXCL12 secreted by CAFs promotes angiogenesis and recruitment of additional inflammatory cells (20) . Kojima et al. reported that CXCL12 plays a role in the maintenance of the CAF phenotype through formation of an auto-stimulatory loop (19) . Furthermore, CXCL12 has recently emerged as a therapeutic target in various cancers (41) (42) (43) . However, the transcription factor that regulates CXCL12 remains unknown. In the present study, we showed that CXCL12 was transcriptionally regulated by Twist1 and the expressions of CXCL12 and Twist1 were significantly correlated to each other in cancer tissues with significant clinical relevance. In our previous study, we examined the genome-wide transcriptional regulation by Twist1 in synovial sarcoma combining both ChIP-SEQ (chromatin immunoprecipitationsequencing) and mRNA array (23) . In that study, we found that Twist1 upregulated CXCL12 expression in synovial sarcoma and bound to a similar sequence in the proximal E-box site (í509 bp), which strongly supports the results of the present study (23) . Fibroblast is a highly heterogeneous entity. Chang et al. showed that fibroblasts from different anatomical regions display characteristic different phenotypes (44) . In addition to the differences between fibroblasts from different anatomical sites, fibroblasts separated from a single tissue are not composed of a homogeneous population (45) . Likewise, the expressional profiles of CAFs may show considerable heterogeneity depending on the anatomical region. Therefore, fibroblasts and CAFs used in study should be derived from the same organ to minimize unexpected bias (3) . In the present study, we established primary fibroblast and CAF cultures from gastric cancer tissues to study the interaction between gastric cancer cells and CAFs.
In conclusion, we identified Twist1 as a novel and key transcription factor that regulates CAFs. Based on our results, Twist1 is suggested as a potent therapeutic target to reverse unfavorable reprogramming of cancer microenvironment. 
